The double-masked parallel-group study of 406 patients with anterior chamber cell grade two or higher at 17 U.S. sites showed 30.5 percent of gel-treated patients and 16.3 percent in the vehicle group had completely recovered from ACC by day eight. By the same time, nearly three-quarters of the first group and 41.9 percent of the second had grade 0 pain. No discomfort on drop instillation was reported by 85 percent of patients.
More Articles on Ophthalmology:
San Antonio Eye Center Adds New Office
Houston Ophthalmologists Named ‘Best Doctors’
Reduced-Fluence Laser Therapy For PCV Patients Improves, Maintains Visual Acuity in 2-Year Follow-Up Study
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
